World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
111
Citations
53401
World Ranking
5279
National Ranking
169

Overview

Marco Colleoni is affiliated with the European Institute of Oncology in Italy. Their research primarily focuses on oncology, with significant contributions in advanced breast cancer therapies and treatment studies. Their work intersects several scientific fields, including medicine, biochemistry, genetics, and molecular biology. Subfields within their expertise include oncology, pulmonary and respiratory medicine, cancer research, genetics, and radiology, nuclear medicine, and imaging.

The scientist's publication record reveals a strong presence in leading cancer research journals. They frequently publish in venues such as Cancer Research, Annals of Oncology, Journal of Clinical Oncology, Clinical Cancer Research, and The Breast.

Marco Colleoni has co-authored numerous papers with recurring collaborators, including Giuseppe Viale, Meredith M. Regan, Richard D. Gelber, Lucia Del Mastro, and Martine Piccart.

Key research topics covered by Marco Colleoni include:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Estrogen and related hormone effects

Recent publications by Marco Colleoni include:

  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021, 2021, Annals of Oncology
  • Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer, 2021, Annals of Oncology
  • Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer, 2022, Annals of Oncology
  • Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes, 2023, JAMA Oncology
  • Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study, 2022, Annals of Oncology

Best Publications

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro

  • Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

    Viviana Galimberti;Bernard F. Cole;Bernard F. Cole;Stefano Zurrida;Giuseppe Viale;Giuseppe Viale

  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

  • Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

    Alan S. Coates;Aparna Keshaviah;Beat Thürlimann;Henning Mouridsen

  • Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    Nicholas C Turner;Dennis J Slamon;Jungsil Ro;Igor Bondarenko

  • Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

    Mitch Dowsett;Jack Cuzick;Jim Ingle;Alan Coates

  • Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

    Debu Tripathy;Seock Ah Im;Marco Colleoni;Fabio Franke

  • Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

    Seock-Ah Im;Yen-Shen Lu;Aditya Bardia;Nadia Harbeck

  • Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

    Olivia Pagani;Meredith M. Regan;Barbara A. Walley;Gini F. Fleming

  • Adjuvant ovarian suppression in premenopausal breast cancer

    Prudence A. Francis;Prudence A. Francis;Meredith M. Regan;Gini F. Fleming;István Láng

  • Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

    P. A. Francis;P. A. Francis;O. Pagani;G. F. Fleming;B. A. Walley

  • Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

    M. Colleoni;A. Rocca;M. T. Sandri;L. Zorzino

  • Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019

    H.J. Burstein;G. Curigliano;S. Loibl;P. Dubsky

  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

    H J Burstein;G Curigliano;B Thürlimann;W P Weber

  • Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V

    Marco Colleoni;Zhuoxin Sun;Karen N. Price;Per Karlsson

  • Very young women (<35 years) with operable breast cancer: features of disease at presentation

    M. Colleoni;N. Rotmensz;C. Robertson;L. Orlando

  • Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents

    Yuval Shaked;Erik Henke;Jeanine M.L. Roodhart;Patrizia Mancuso

  • International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?

    Olivia Pagani;Elżbieta Senkus;William Wood;Marco Colleoni

  • Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

    D. Miles;J. Gligorov;F. André;D. Cameron

Frequent Co-Authors

Giuseppe Viale
Giuseppe Viale University of Milan
Aron Goldhirsch
Aron Goldhirsch European Institute of Oncology
Paolo Veronesi
Paolo Veronesi European Institute of Oncology
Richard D. Gelber
Richard D. Gelber Harvard University
Alan S. Coates
Alan S. Coates University of Sydney
Vincenzo Bagnardi
Vincenzo Bagnardi University of Milano-Bicocca
Meredith M. Regan
Meredith M. Regan Harvard University
Karen N. Price
Karen N. Price Frontier Science Foundation
Nicole Rotmensz
Nicole Rotmensz European Institute of Oncology
Giancarlo Pruneri
Giancarlo Pruneri University of Milan

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens up a wide range of online health-related degree options, providing flexibility and accessibility for aspiring professionals. One popular path is through affordable online nursing programs, which help students gain valuable clinical skills while managing costs compared to traditional on-campus degrees.

For registered nurses seeking to advance their education, exploring the average cost of rn to bsn programs is essential. These programs allow RNs to earn a Bachelor of Science in Nursing online, often at a lower price point.

Non-nursing professionals interested in making a career switch may benefit from direct entry online msn programs. These accelerated pathways are tailored for those without prior nursing backgrounds, helping candidates enter the nursing field quickly.

For those aiming for leadership or academic roles, phd nursing programs offer advanced online study with a focus on research, teaching, or executive practice, usually at a more affordable rate than traditional PhD routes.

Best Scientists Citing Marco Colleoni

Trending Scientists